BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line Q4 on the top line, driving 9% and 12% Y/Y operational organic top line and EPS growth, respectively, with key highlights for Zoetis in 2024 that included driving strong growth in its companion animal business, which grew 14% Y/Y operationally, 28% Y/Y growth from its Simparica franchise, and 17% Y/Y growth from its key dermatology franchise, but its 2025 guide came in below the Street due to the divestiture and FX, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Zoetis Reports Robust Growth Amid Challenges
- Zoetis reports conditional license from USDA for Avian Influenza Vaccine
- Zoetis price target lowered to $200 from $205 at BofA
- Zoetis: Strong Buy Rating Backed by Solid Financial Performance and Promising Growth Prospects
- Zoetis price target raised to $244 from $242 at Barclays